Biotechnology News and Research

RSS

Intrexon announces AgBio Division launch and Agarigen acquisition

Intrexon Corporation, a next generation synthetic biology company, today announced the launch of its Agricultural Biotechnology (AgBio) Division in Research Triangle Park, North Carolina and the acquisition of Agarigen, Inc., a North Carolina-based company that has developed a novel, mushroom-based expression platform for the rapid, high yield production of recombinant proteins.

2 Feb 2011

FDA, Optivia collaborate to examine effect of dietary supplements in drug-induced liver injury

Optivia Biotechnology, a leading provider of in vitro transporter assay services, today announced that the company and the U.S. Food and Drug Administration have signed a collaboration agreement to assess the effect of dietary supplements on key drug transporters.

1 Feb 2011

Seattle Genetics to sell common stock in underwritten public offering

Seattle Genetics, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Seattle Genetics.

1 Feb 2011

Genzyme's diagnostic products sold to Sekisui Chemical for $265 million

Genzyme Corporation today announced that it has completed the sale of its diagnostic products business to Sekisui Chemical Co., Ltd. for $265 million in cash.

1 Feb 2011

Positive interim results from H5N1 Avian Influenza VLP vaccine Phase II human clinical trial

Medicago, a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today reported positive interim results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate.

1 Feb 2011

Positive interim results from Medicago's Phase II clinical trial of H5N1 Avian Influenza VLP vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine"). The vaccine was found to be safe, well tolerated and also induced a solid immune response.

1 Feb 2011

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2010 results.

1 Feb 2011

Discovery Labs provides expanded update on efforts to gain FDA marketing authorization for Surfaxin in RDS

Discovery Laboratories, Inc. is providing an expanded update regarding ongoing efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization for Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.

1 Feb 2011

PhRMA: 299 medicines under development for prevention and treatment of heart disease and stroke

An American dies of heart disease every 39 seconds, and African Americans suffer a higher death rate from heart disease and stroke than Americans overall. Partly as a result of having the highest prevalence of high blood pressure in the world, African Americans have a 1.5 times greater rate of heart disease death than other Americans and a 1.8 times greater rate of fatal stroke.

1 Feb 2011

Circassia Phase II clinical trial confirms safety profile of ToleroMune cat allergy treatment

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that the company's ToleroMune(R) cat allergy treatment significantly reduced patients' symptoms in a recently completed, large-scale phase II clinical trial. The study also confirmed the treatment's highly favourable safety profile.

1 Feb 2011

Genzyme, Sanofi-Aventis enter confidentiality agreement

Genzyme Corp. announced today that ongoing discussions with Sanofi-Aventis have progressed to the point where Genzyme's board has authorized the company to enter into a confidentiality agreement with Sanofi-Aventis in order to allow Sanofi to conduct due diligence. Discussions between Genzyme's advisors and Sanofi's advisors and between Genzyme and Sanofi representatives are continuing.

1 Feb 2011

FDA schedules panel meeting date for BioMimetic Therapeutics's Augment Bone Graft PMA

BioMimetic Therapeutics, Inc., today announced that the U.S. Food and Drug Administration (FDA) has tentatively scheduled an Orthopedic and Rehabilitation Devices Panel meeting on May 12, 2011 to review the Company's Premarket Approval (PMA) application for Augment™ Bone Graft for the treatment of foot and ankle fusions in the U.S.

1 Feb 2011

Eurogentec, ImaginAb announce collaboration to produce engineered antibody fragments

ImaginAb, and Eurogentec S.A. announce a development collaboration to establish a novel system for producing engineered antibody fragments. The two companies will produce ImaginAb's optimized antibody fragments with Eurogentec's high-performance Pichia pastoris expression system.

1 Feb 2011

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the initiation of two studies to further evaluate the efficacy and safety of VB-111 in advanced cancers.

31 Jan 2011

Baxter launches OLIMEL emulsion for parenteral nutrition

Baxter International today announced the launch of OLIMEL emulsion for infusion in Canada at the American Society of Parenteral and Enteral Nutrition's Clinical Nutrition Week.

From Baxter International Inc. 31 Jan 2011

Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis

Maxygen, a biotechnology company focused on the development of improved protein drugs, today announced the initiation of a Phase I clinical study to evaluate a next-generation CTLA4-Ig therapeutic that is being developed by Perseid Therapeutics LLC, Maxygen's majority-owned subsidiary, in collaboration with Astellas Pharma Inc. for the treatment of rheumatoid arthritis and potentially other autoimmune indications.

31 Jan 2011

Alexion announces acquisition of Taligen Therapeutics

Alexion Pharmaceuticals, announced that it has acquired Taligen Therapeutics, a privately held development-stage biotechnology company based in Cambridge, Mass.

31 Jan 2011

EVP of Advaxis' Science & Operations moderates Live Cancer Vaccines panel discussion

Dr. John Rothman, EVP of Science & Operations of Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, moderated a panel discussion titled, "Live Cancer Vaccines."

29 Jan 2011

BIO President comments on introduction of Patent Reform Act of 2011

Biotechnology Industry Organization President and CEO Jim Greenwood released the following comment on the introduction of the Patent Reform Act of 2011 (S. 23) by Senate Judiciary Committee Chairman Patrick Leahy (D-VT) earlier this week

29 Jan 2011

NexMed presents data on NexACT technology use to improve less permeable, soluable oral drugs

Apricus Biosciences, today announced that its research and development team at its NexMed, USA, Inc. subsidiary is presenting data demonstrating the use of the Company's proprietary NexACT technology to improve less permeable or less soluable drugs, at the Controlled Release Society Product Development Forum for Poorly Soluble Drugs, being held January 27 to 29, 2011, in Miami, Florida.

29 Jan 2011

Biotechnology News and Research

Intrexon announces AgBio Division launch and Agarigen acquisition

FDA, Optivia collaborate to examine effect of dietary supplements in drug-induced liver injury

Seattle Genetics to sell common stock in underwritten public offering

Genzyme's diagnostic products sold to Sekisui Chemical for $265 million

Positive interim results from H5N1 Avian Influenza VLP vaccine Phase II human clinical trial

Positive interim results from Medicago's Phase II clinical trial of H5N1 Avian Influenza VLP vaccine

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Discovery Labs provides expanded update on efforts to gain FDA marketing authorization for Surfaxin in RDS

PhRMA: 299 medicines under development for prevention and treatment of heart disease and stroke

Circassia Phase II clinical trial confirms safety profile of ToleroMune cat allergy treatment

Genzyme, Sanofi-Aventis enter confidentiality agreement

FDA schedules panel meeting date for BioMimetic Therapeutics's Augment Bone Graft PMA

Eurogentec, ImaginAb announce collaboration to produce engineered antibody fragments

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

Baxter launches OLIMEL emulsion for parenteral nutrition

Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis

Alexion announces acquisition of Taligen Therapeutics

EVP of Advaxis' Science & Operations moderates Live Cancer Vaccines panel discussion

BIO President comments on introduction of Patent Reform Act of 2011

NexMed presents data on NexACT technology use to improve less permeable, soluable oral drugs

Biotechnology eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News